77P A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumabM. Persano, A. Casadei Gardini, Stefano Tamberi et al.|Immuno-Oncology Technology|2024Cited by 0
109P Prognostic impact of target-directed therapies in biliary tract cancer patients harboring molecular alterationsSilvia Camera, A. Casadei-Gardini, M. Rimini et al.|ESMO Open|2025Cited by 0
328P Time toxicity (TT) associated with first-line treatment (1L) in patients (pts) with advanced biliary tract cancer (aBTC)Naohiro Okano, Mitesh J. Borad, Anna Virginia Adriana Pirozzi et al.|Annals of Oncology|2025Cited by 0
353P Prognostic role of metastatic sites in a worldwide population of patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumabSilvia Camera, Lorenzo Fornaro, M. Rimini et al.|Annals of Oncology|2025Cited by 0
104eP A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumabM. Persano, A. Casadei Gardini, M. Rimini et al.|Annals of Oncology|2025Cited by 0